newsfilter
← Latest News
Business Wire·

TNF Pharmaceuticals Delivers Podium Presentation of Novel Oral TNF-Alpha Inhibitor at Premier International Conference on Frailty and Sarcopenia

Positive clinical data validates current Phase 2b clinical trial of isomyosamine as a treatment for chronic inflammation associated with muscle loss TNF Pharmaceuticals, Inc. (NASDAQ:TNFA) ("TNF" or the "Company"), a